Our platform technologies, TROCAD™ and TROSIG™, are expected to improve the therapeutic index by reducing toxicity and improving efficacy simultaneously. TROCAD™ is TriOar's proprietary dual-function conditionally activatable domain (CAD) that achieves both masking and guiding effects simultaneously. This results in a lower on/off target toxicity and higher antitumor efficacy, leading to an increased therapeutic index. TROCAD™ is modular, which means it can be applied to various modalities such as antibody-drug conjugates (ADC) and immuno-oncology, and maintains molecular stability. TROSIG™ is a novel self-immolative group that works with various functional groups, triggering groups, and payloads. TROSIG™-ADCs have proven to be highly stable in circulation and demonstrated excellent potencies in both in-vitro and in-vivo. Pipeline programs are anti-CLDN18.2 ADC and anti-EGFR ADC